Syndax Pharmaceuticals Inc [SNDX] stock prices are up 1.23% to $23.86 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SNDX shares have gain 4.01% over the last week, with a monthly amount glided 7.96%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, March 2024, Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2024 the Company granted inducement awards to purchase up to 42,800 shares of common stock to three new employees under the Company’s 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee’s continued service relationship with Syndax through the applicable vesting dates.
From an analyst’s perspective:
Syndax Pharmaceuticals Inc [NASDAQ: SNDX] stock has seen the most recent analyst activity on January 31, 2024, when Scotiabank downgraded its rating to a Sector Perform and also revised its price target to $23 from $36. Previously, Mizuho started tracking the stock with Buy rating on December 22, 2023, and set its price target to $45. On October 25, 2023, BofA Securities initiated with a Buy rating and assigned a price target of $29 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $30 on October 11, 2023. Scotiabank initiated its recommendation with a Sector Outperform. Guggenheim started tracking with a Buy rating for this stock on July 11, 2023, and assigned it a price target of $40.
The stock price of Syndax Pharmaceuticals Inc [SNDX] has been fluctuating between $11.22 and $25.34 over the past year. Currently, Wall Street analysts expect the stock to reach $37.67 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $23.86 at the most recent close of the market. An investor can expect a potential return of 57.88% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.47 and Total Capital is -0.41. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.25 points at the first support level, and at 22.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.28, and for the 2nd resistance point, it is at 24.69.
Syndax Pharmaceuticals Inc [SNDX] reported earnings per share of -$1 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.99/share, meaning a difference of -$0.01 and a surprise factor of -1.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.73 per share as compared to estimates of -$0.79 per share, a difference of $0.06 representing a surprise of 7.60%.
Ratios To Look Out For
It’s worth pointing out that Syndax Pharmaceuticals Inc [NASDAQ:SNDX]’s Current Ratio is 10.00. Further, the Quick Ratio stands at 10.00, while the Cash Ratio is 5.08.
Transactions by insiders
Recent insider trading involved Morrison Briggs, Director, that happened on Aug 09 ’23 when 52855.0 shares were sold. Director, Meury William completed a deal on Aug 02 ’23 to sell 83000.0 shares. Meanwhile, Director Morrison Briggs sold 52855.0 shares on Jul 10 ’23.
